Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Lymphoma, Intermediate-Grade

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lymphoma, Intermediate-Grade

Examination of other lymphoid tumours revealed that most high grade lymphomas, but not most low or intermediate grade lymphomas, do not express the LFA-1 molecule [1].
Gallium-67 sensitivity for low-grade lymphoma was significantly less than for Hodgkin's and intermediate grade lymphomas [2].
Due to the variation in the proportion of S-phase cells in the intermediate grade and high grade, as well as the UP lymphomas, only approximately 50% of the UP and 60% of the high-grade lymphomas were identified as such by this discriminant model, while almost one half of the intermediate-grade lymphomas were allocated to the low-grade group [3].

High impact information on Lymphoma, Intermediate-Grade

Patients with intermediate-grade lymphoma or in Richter's transformation received cisplatin 25 mg/m2 daily for 4 days; fludarabine 30 mg/m2; and cytarabine 500 mg/m2 daily for 2 days [4].
PURPOSE: To determine whether modifying the standard regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) from full doses given every 3 weeks to one-third doses given weekly (chop) increases the received chemotherapy dose-intensity in elderly patients with advanced-stage intermediate-grade lymphoma [5].
For those patients with low and intermediate grade lymphomas and with mean S-phase values < 10.0%, we found that mean S-phase was higher during winter (5.8 +/- 0.4%) than during spring (3.8 +/- 0.3%) or during fall (3.6 +/- 0.3%) (P < 0.001, analysis of variance) [6].
PATIENTS AND METHODS: Nineteen patients with low- or intermediate-grade lymphomas were treated with bolus high-dose IL-2 alone (11 patients) or IL-2 with LAK cells (eight patients) [7].
FDG uptake was comparable for both the low- and intermediate-grade lymphomas [8].

Biological context of Lymphoma, Intermediate-Grade

To assess the role of mdr gene products in drug resistance in canine lymphoma, membrane preparations of lymphoma cells from 31 dogs with high- or intermediate-grade lymphoma were subjected to Western blotting for detection of P-glycoprotein [9].

Anatomical context of Lymphoma, Intermediate-Grade

We analysed the frequencies of three single base substitutions in the IL-10 promoter in patients with aggressive lymphoma (B-cell DLCL n = 46, other aggressive histologies n = 17), Hodgkin's disease (n = 44) or low/intermediate grade lymphoma (n = 46), compared to healthy controls [10].

Gene context of Lymphoma, Intermediate-Grade

High-grade lymphomas showed a significantly larger number of Ki-67-positive cells than intermediate-grade lymphomas (102.5 +/- 21.6 in high-grade and 46.8 +/- 8.92 in intermediate-grade lymphomas, P = 0.03), even when analyzed separately by immunophenotypes [11].
A proportion (4/9) of "intermediate grade" lymphomas had 10-15% TR positivity [12].

References

Absence of cell surface LFA-1 as a mechanism of escape from immunosurveillance. Clayberger, C., Wright, A., Medeiros, L.J., Koller, T.D., Link, M.P., Smith, S.D., Warnke, R.A., Krensky, A.M. Lancet (1987) [Pubmed]
Comparison of gallium-67-citrate and thallium-201 scintigraphy in peripheral and intrathoracic lymphoma. Waxman, A.D., Eller, D., Ashook, G., Ramanna, L., Brachman, M., Heifetz, L., McAndrews, P., Bierman, H., Taub, R., Avedo, M., Wall, F. J. Nucl. Med. (1996) [Pubmed]
Cell proliferation and DNA content in non-Hodgkin's lymphoma. Flow cytometry in relation to lymphoma classification. Christensson, B., Tribukait, B., Linder, I.L., Ullman, B., Biberfeld, P. Cancer (1986) [Pubmed]
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. Khouri, I.F., Keating, M., Körbling, M., Przepiorka, D., Anderlini, P., O'Brien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Donato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A., Champlin, R. J. Clin. Oncol. (1998) [Pubmed]
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. Meyer, R.M., Browman, G.P., Samosh, M.L., Benger, A.M., Bryant-Lukosius, D., Wilson, W.E., Frank, G.L., Leber, B.F., Sternbach, M.S., Foster, G.A. J. Clin. Oncol. (1995) [Pubmed]
DNA synthesis and ploidy in non-Hodgkin's lymphomas demonstrate intrapatient variation depending on circadian stage of cell sampling. Smaaland, R., Lote, K., Sothern, R.B., Laerum, O.D. Cancer Res. (1993) [Pubmed]
The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. Weber, J.S., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., White, D.E., Rosenberg, S.A. J. Clin. Oncol. (1992) [Pubmed]
Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Newman, J.S., Francis, I.R., Kaminski, M.S., Wahl, R.L. Radiology. (1994) [Pubmed]
The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Moore, A.S., Leveille, C.R., Reimann, K.A., Shu, H., Arias, I.M. Cancer Invest. (1995) [Pubmed]
Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Cunningham, L.M., Chapman, C., Dunstan, R., Bell, M.C., Joske, D.J. Leuk. Lymphoma (2003) [Pubmed]
The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Yamanaka, N., Harabuchi, Y., Kataura, A. Cancer (1992) [Pubmed]
Correlation of transferrin receptor expression with histologic grade and immunophenotype in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Das Gupta, A., Shah, V.I. Hematologic pathology. (1990) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.